Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | Healthcare utilization & end of life outcomes in patients receiving CAR-T

Connor Johnson • 5 Feb 2021
TCT 2021
Lymphoma

Connor Johnson, MD, Massachusetts General Hospital & Harvard Medical School, Boston, MA, outlines the results of a retrospective analysis evaluating the impact of CAR T-cell therapy on healthcare utilization and end-of-life outcomes. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Connor Johnson

3:25
Association between baseline PROs & complications of HSCT
Connor Johnson • 5 Feb 2021

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals